Sustained modulation of the inflammatory microenvironment for cartilage repair using an ROS-responsive hydrogel delivering CircSERPINE2-loaded exosomes
Source abstract
Abstract
Osteoarthritis (OA) involves chronic inflammation and oxidative stress, both of which impair cartilage regeneration. To counteract these pathological processes, bone marrow mesenchymal stromal cell (BMSC)-derived exosomes have emerged as a promising therapy. These exosomes promote chondrogenesis and facilitate chemokine-guided cell homing. However, hostile microenvironments compromise their efficacy. This study developed a cell-free, ROS-responsive boronate-vinyl (BV) hydrogel platform encapsulating BMSC-derived exosomes overexpressing CircSERPINE2 (BV@cSERPINE2-Exo), which were isolated via ultracentrifugation from lentivirus-transduced BMSCs. This platform enables sustained microenvironmental modulation and functional cartilage regeneration. The hydrogel forms through dynamic boronate ester crosslinking between phenylboronic acid-modified poly γ-glutamic acid and polyvinyl alcohol (PVA). It exhibits rapid gelation, shear-thinning injectability, and potent ROS-scavenging capacity. ROS-triggered cleavage of the boronate ester bonds ensures controlled exosome release. In vitro, BV@cSERPINE2-Exo shifted LPS-stimulated macrophages from an M1 to M2 phenotype by decreasing iNOS and IL-1β levels and increasing Arg-1 and IL-10. Concurrently, the system protected chondrocytes from TNF-α-induced degeneration by downregulating MMP13 and restoring COL2A1, SOX9, and proteoglycan synthesis. In a rat patellar cartilage defect model, intra-articular injection of BV@cSERPINE2-Exo promoted deposition of cartilage-specific extracellular matrix and achieved near-complete hyaline cartilage-like repair within 8 weeks. This repair was superior to that in the BV hydrogel or unmodified exosome control groups. These results establish a smart, injectable biomaterial strategy that integrates precise ROS-responsive circRNA delivery with immunomodulation, offering a promising early intervention strategy for cartilage defect repair and the prevention of osteoarthritis progression.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Osteoarthritis Treatment and Mechanisms · Extracellular vesicles in disease · Total Knee Arthroplasty Outcomes
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (45)
Show source-provided references
1. Subchondral bone microenvironment in osteoarthritis and pain10.1038/s41413-021-00147-z ↗
2. Hydrogels for ameliorating osteoarthritis: mechanical modulation, anti-inflammation, and regeneration10.1002/bmm2.12078 ↗
3. Advancements in tissue engineering for articular cartilage regeneration10.1016/j.heliyon.2024.e25400 ↗
4. Fundamentals of osteoarthritis: inflammatory mediators in osteoarthrit is10.1016/j.joca.2023.06.005 ↗
5. Biodegradable and non-biodegradable biomaterials and their effect on cell differentiation10.3390/ijms232416185 ↗
6. Biomaterial scaffolds for therapeutic immune cell engineering and deli very10.1016/j.jconrel.2025.114072 ↗
7. The engineered bone marrow mesenchymal stem cell-derived exosome: a new strategy for the treatment of inflammatory diseases10.1016/j.intimp.2025.115136 ↗
8. Stem cell-derived exosomes: emerging therapeutic opportunities for wound healing10.1186/s13287-023-03345-0 ↗
9. Engineered exosome-mediated delivery of functionally active miR-26a and its enhanced suppression effect in HepG2 cells10.2147/IJN.S154458 ↗
10. M1 macrophage-derived exosomes impair beta cell insulin secretion via miR-212-5p by targeting SIRT2 and inhibiting Akt/GSK-3β/β-catenin pathway in mice10.1007/s00125-021-05489-1 ↗
11. PRDM paralogs antagonistically balance Wnt/β-catenin activity during craniofacial chondrocyte differentiation10.1242/dev.200082 ↗
12. Injectable mussel-inspired highly adhesive hydrogel with exosomes for endogenous cell recruitment and cartilage defect regeneration10.1016/j.biomaterials.2021.121169 ↗
13. Horizon of exosome-mediated bone tissue regeneration: the all-rounder role in biomaterial engineering
14. Progenitor cell-derived exosomes endowed with VEGF plasmids enhance os teogenic induction and vascular remodeling in large segmental bone defects10.7150/thno.50741 ↗
15. Recent advances in exosome-mediated nucleic acid delivery for cancer therapy10.1186/s12951-022-01472-z ↗
16. Therapeutic potential of RNA-enriched extracellular vesicles: the next generation in RNA delivery via biogenic nanoparticles10.1016/j.ymthe.2024.02.025 ↗
17. M2 macrophage-derived exosomal miR-26b-5p regulates macrophage polarization and chondrocyte hypertrophy by targeting TLR3 and COL10A1 to alleviate osteoarthritis10.1186/s12951-024-02336-4 ↗
18. Integration of microRNAs with nanomedicine: tumor targeting and therapeutic approaches10.3389/fcell.2025.1569101 ↗
19. Structural basis for target-directed microRNA degradation10.1016/j.molcel.2019.06.019 ↗
20. Circular RNA: an emerging frontier in RNA therapeutic targets, RNA the rapeutics, and mRNA vaccines10.1016/j.jconrel.2022.05.043 ↗
21. CircSERPINE2 protects against osteoarthritis by targeting miR-1271 and ETS-related gene10.1136/annrheumdis-2018-214786 ↗
22. Exosomes, DAMPs and miRNA: features of stress physiology and immune ho meostasis10.1016/j.it.2017.08.002 ↗
23. Crosstalk between oxidative stress and exosomes
24. Exosomes loaded a smart bilayer-hydrogel scaffold with ROS-scavenging and macrophage-reprogramming properties for repairing cartilage defect
25. Reactive oxygen species (ROS) scavenging biomaterials for anti-inflammatory diseases: from mechanism to therapy10.1186/s13045-023-01512-7 ↗
26. Reactive oxygen species, aging and articular cartilage homeostasis10.1016/j.freeradbiomed.2018.08.038 ↗
27. LDHA-mediated ROS generation in chondrocytes is a potential therapeutic target for osteoarthritis10.1038/s41467-020-17242-0 ↗
28. Exosome for mRNA delivery: strategies and therapeutic applications10.1186/s12951-024-02634-x ↗
29. A multifunctional γ-polyglutamic acid hydrogel for combined tumor phot othermal and chemotherapy10.3390/gels11030217 ↗
30. Macrophage polarization in rheumatoid arthritis: signaling pathways, metabolic reprogramming, and crosstalk with synovial fibroblasts10.3389/fimmu.2024.1394108 ↗
31. The role of metabolism in chondrocyte dysfunction and the progression of osteoarthritis
32. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteo arthrosis!)10.1016/j.joca.2012.11.012 ↗
33. Matrix stiffening promotes chondrocyte senescence and the osteoarthritis development through downregulating HDAC310.1038/s41413-024-00333-9 ↗
34. CircSERPINE2 weakens IL-1β-caused apoptosis and extracellular matrix degradation of chondrocytes by regulating miR-495/TGFBR2 axis10.1042/BSR20201601 ↗
35. Circular RNA PVT1 promotes osteoarthritis progression through the miR-550a-3p/CX3CR1 pathway: a mechanistic study10.1016/j.intimp.2025.115272 ↗
36. CircRNAs: role in human diseases and potential use as biomarkers10.1038/s41419-021-03743-3 ↗
37. circSP199a, a circularized RNA sponge targeting miR-199a-5p and -3p, m itigates mouse cardiac hypertrophy and fibrosis10.1038/s41401-025-01620-9 ↗
38. Cartilage-penetrating framework nucleic acid nanoparticles ameliorate osteoarthritis by promoting drug delivery and chondrocyte uptake10.1002/advs.202502661 ↗
39. Advances in locally administered nucleic acid therapeutics
40. Injectable exosome-reinforced konjac glucomannan composite hydrogel for repairing cartilage defect: activation of endogenous antioxidant pathways10.1093/rb/rbaf060 ↗
41. Clinical implications of macrophage dysfunction in the development of osteoarthritis of the knee10.1016/j.cytogfr.2019.03.004 ↗
42. Macrophages regulate the progression of osteoarthritis10.1016/j.joca.2020.01.007 ↗
43. LATS1-modulated ZBTB20 perturbing cartilage matrix homeostasis contributes to early-stage osteoarthritis10.1038/s41413-025-00414-3 ↗
44. CIP2A promotes inflammation and exacerbates osteoarthritis by targeting CEMIP10.1186/s11658-025-00748-0 ↗
45. The immune microenvironment in cartilage injury and repair10.1016/j.actbio.2021.12.006 ↗